№ lp_1_2_45809
File format: docx Character count: 36753 File size: 78 KB
Comparative clinical reference outlining licensed indications, pharmacological properties, dosing considerations, administration methods, and safety aspects of direct oral anticoagulants and warfarin based on regulatory and clinical guidance.
Document type: Clinical guidance
Subject: Anticoagulant medicines
Therapeutic areas: Atrial fibrillation; venous thromboembolism; acute coronary syndrome
Medicines covered: Dabigatran; Rivaroxaban; Apixaban; Edoxaban; Warfarin
Regulatory references: NICE technology appraisals
Indications: Stroke prevention; treatment and prevention of DVT and PE; post-surgical VTE prevention; atherothrombotic event prevention
Dosage considerations: Renal function; body weight; hepatic impairment
Route of administration: Oral
Reversal information: Included
Drug interactions: Included
Contraindications: Included
Target audience: Healthcare professionals
Geographic context: United Kingdom
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.

Don’t have cryptocurrency yet?

You can still complete your purchase in a few minutes:
  1. Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
  2. In the app, tap Send.
  3. Select network, paste our wallet address.
  4. Send the exact amount shown above.
After sending, paste your TXID (transaction ID) and your email to receive the download link. Need help? Contact support and we’ll guide you step by step.

The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Atrial fibrillation: DOACs and vitamin K antagonists
Year: 2022
Region / city: England
Topic: Atrial fibrillation, anticoagulation therapy
Document type: Indicator guidance
Organization / institution: NICE
Author: NICE
Target audience: Healthcare professionals, general practitioners
Validity period: Until November 2025
Approval date: November 2022
Date of changes: N/A
Source guidance: NICE’s guideline on atrial fibrillation (2021) recommendations 1.6.3 and 1.6.5
Specification: CVD-05 indicator, Impact and Investment Fund 2022/23
Exclusions: People with resolved atrial fibrillation, valvular atrial fibrillation, recorded antiphospholipid syndrome
Note: Contextual description
High-Risk Medicine Standard- Heparin and other Anticoagulants
Note: Year
Region / city: Canberra
Subject: Anticoagulant medicines, High-Risk Medicines
Document type: Procedure
Organization / institution: Canberra Health Services
Target audience: Health professionals involved in prescribing, dispensing, and administering anticoagulants
Context: This document provides guidelines on the safe management of high-risk anticoagulant medicines in Canberra Health Services to prevent prescription, dispensing, and administration errors.
Management of Dental Patients Taking Anticoagulants or Antiplatelet Drugs
Year: 2015
Region / city: Scotland
Topic: Dental care, anticoagulants, antiplatelet drugs
Document Type: Clinical guidance
Organization / Institution: Scottish Dental Clinical Effectiveness Programme (SDCEP)
Author: Scottish Dental Clinical Effectiveness Programme
Target Audience: Dental professionals
Period of Validity: 2015
Date of Approval: August 2015
Date of Amendments: Not specified
Community Counselling and Commencing of Oral Anticoagulants for Atrial Fibrillation in Newham, 1st April 2020 – 31st March 2021
Year: 2020–2021
Region: Newham, UK
Theme: Community health services, Atrial fibrillation, Anticoagulant therapy
Document Type: Service specification
Organization: Newham Clinical Commissioning Group (CCG)
Author: NHS commissioning team
Target audience: Healthcare providers, community pharmacists, GPs
Period of validity: 1st April 2020 – 31st March 2021
Review date: Not specified
Scope: Initiation and counselling of oral anticoagulants for patients with atrial fibrillation
Clinical guidelines referenced: NICE Guidelines, British Committees of Haematology (BCSH), National Patient Safety Agency (NPSA)
Population covered: Patients registered with Newham GP practices
Service objectives: Improve access, patient education, reduce inequalities, enhance quality of care, maintain communication across health professionals
Care pathway: Acute specialist team initiates therapy, community service manages ongoing care, includes counselling, monitoring, and documentation
Exclusion criteria: Patients deemed clinically unsafe for outpatient management
Predictors of intracranial haemorrhage in patients with atrial fibrillation treated with oral anticoagulants: GARFIELD-AF and ORBIT-AF registry data
Year: 2026
Region / city: International multicenter
Topic: Cardiology, Hematology
Document type: Supplementary tables and figures
Institution: GARFIELD-AF and ORBIT-AF study groups
Authors: Multi-center registry investigators
Target audience: Clinicians, researchers
Study period: 2 years follow-up
Data collection: Patient registries
Patient population: Adults with atrial fibrillation receiving oral anticoagulants
Measured outcomes: Incidence of intracranial hemorrhage, baseline characteristics, treatment type, comorbidities, vital signs
Data analysis: Risk factor association with intracranial hemorrhage
Treatment types: NOAC, VKA, concomitant antiplatelet therapy
Topics: Warfarin DOACs Anticoagulants